Hematology

Publications

Alharbi, S; Merkle, S; Hammill, AM; Waters, AM; Le Cras, TD. RAS Pathway Mutations and Therapeutics in Vascular Anomalies. Pediatric Blood and Cancer. 2025; 72(5):e31605.

Al-Samkari, H; Kasthuri, RS; Mager, H-J; Zhou, JY; Serra, MM; Samuelson-Bannow, BT; Van Doren, LN; Piccirillo, JF; Clancy, MS; Mccrae, KR; Mei-Zahav, M; Von Drygalski, A; Olitsky, S; Faughnan, ME. Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report. American Journal of Hematology. 2025; 100(10):1813-1827.

Ambrose, EE; Kidenya, BR; Smart, LR; Manjurano, A. Alpha+ Thalassemia in Northwestern Tanzania: Molecular and Hematological Insights From Newborn Screening. Journal of Blood Medicine. 2025; 16:241-250.

Ambrose, EE; Sabuni, PA; Jason Iii, DP; Ware, RE; Makubi, AN; Smart, LR. Hydroxyurea to decrease stroke risk in children with sickle cell anemia: a systematic review and meta-analysis. Blood Global Hematology. 2025; 1(1).

Ammari, O; Shah, M; Elgammal, Y; Husami, A; Kalfa, TA; Gollamudi, J. When a Trait Becomes a Disease: A Rare Hematologic Overlap of Sickle Cell Trait and Hereditary Spherocytosis. American Journal of Hematology. 2025.

Azucenas, C; Voulgaridou, A; Elgammal, Y; Ntoumaziou, A; Risinger, M; Seu, K; Sen, S; Kottyan, L; Salomonis, N; Kalfa, T. Erythroid-specific, inducible CDAN1∆/∆ mouse model phenocopies congenital dyserythropoietic anemia type-la. Blood. 2025; 146(Supplement 1):186-186.

Belton, TD; Steinway, CM; Teng, O; Shults, J; Barakat, LP; Aygun, B; Appiah-Kubi, A; Crosby, LE; Niss, O; Andemariam, B; Johnson, TB; Rubin, DM; Smith-Whitley, KM; Jan, S. The Community Health Workers and Mobile Health for Emerging Adults Transitioning Sickle Cell Disease Care (COMETS) Trial: Protocol for a Randomized Controlled Trial. JMIR Research Protocols. 2025; 14:e69239.

Boucher, AA; Dayton, VJ; Pratt, AR; Nassar, NN; Elgammal, Y; Kalfa, TA. Three-generation female cohort with macrocytic anemia and iron overload. American Journal of Hematology. 2025; 100(1):133-138.

Boucher, A; Cole, OB; Desai, PC; Donald, C; Fasipe, TA; Quinn, CT; Kennedy Lesch, J; Thompson, AA. ASH's Commitment to SCD: Building on 10 Years of Progress. Blood advances. 2025.

Canaud, G; López-Gutiérrez, JC; Hammill, A; Weibel, L; Niglis, S; Paul, M; Papadimitriou, A; Wroclawska, M; Caro, N; Adams, D. 118: Randomized, Double-Blind, Phase 2 Study of Alpelisib in Pediatric and Adult Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Journal of Investigative Dermatology. 2025; 145(3):e29.

Cantrell, R; Feldman, HA; Rosenfeldt, L; Ali, A; Gourley, B; Sprague, C; Leino, D; Crosby, J; Revenko, A; Monia, B; Waggoner, SN; Palumbo, JS. Prothrombin prevents fatal T cell-dependent anemia during chronic virus infection of mice. JCI Insight. 2025; 10(4).

Chan, AK; Susen, S; Khoo, L; Von Drygalski, A; Oldenburg, J; Shen, M-C; Peyvandi, F; Tarango, C; Chowdary, P; Mamikonian, L; Palmborg, H; Dumont, J; Santagostino, E; Hermans, C. Perioperative Management with Efanesoctocog Alfa in Adults, Adolescents, and Children with Severe Hemophilia A in the Phase 3 XTEND Clinical Program. Hamostaseologie. 2025; 45:s57-s58.

Chang, M; Semakula, D; Little, JA; Kanter, J; Manwani, DG; Owusu-Ansah, A; Cohen, AJ; Cronin, RM; Desai, PC; Strouse, JJ; Alvarez, OA; Saif Ur Rehman, S; Shah, S; Lanzkron, SM. Grandchildren of GRNDaD: Shifts in disease-modifying therapy at the adolescent transition in sickle cell disease. British Journal of Haematology. 2025; 207(3):1070-1075.

Choaib, A; Azzam, M; Khawandi, J; Kawtharany, H; Hamarsha, Q; Alkhader, A; Nazzal, J; Alkasrawi, H; Khanfar, O; Bercovitz, R; Zia, A; Monagle, P; Betensky, M; Mustafa, R. Role in of primary VTE prophylaxis in pediatric patients in hospitalized and critically ill settings: A systematic review and meta-analysis. Blood. 2025; 146(Supplement 1):3137-3137.

Cohen, RM; Craig, J; Omololu, SO; Tozzo, V; Smith, EP; Arbabi, S; Genco, M; Abplanalp, W; Thibault, D; Quinn, CT; Lindsell, CJ; Bergenstal, RM; Franco, RS; Higgins, J. 166-OR: Mean RBC Age (MRBC) Variation Accounts for the Predominance of Mismatch (MM) between Measured HbA1c (mA1c) and CGM-Derived Estimated HbA1c (eA1c) Diabetes. 2025; 74(Supplement_1).

Coleman, KD; Mckinley, K; Ellison, AM; Alpern, ER; Hariharan, S; Topoz, I; Wurtz, M; Nielsen, B; Cook, LJ; Morris, CR; King, AA; Baumann, A; Frankenberger, W; Brousseau, DC. Associations Between Pain Scores and Opioid Doses With Emergency Department Disposition and Return Visit Rates in Children With Sickle Cell Disease. Pediatric Blood and Cancer. 2025; 72(7):e31750.

Costa, E; Ware, R; Tshilolo, L; Luzzatto, L. Thirty Years of Hydroxyurea for Sickle Cell Anemia - Scientific Progress, Global Health Gaps. New England Journal of Medicine. 2025; 393(16):1556-1559.

Costa, E; Ware, RE; Tshilolo, L; Makani, J; Leufkens, HGM; Luzzatto, L. Globalization in clinical drug development for sickle cell disease. American Journal of Hematology. 2025; 100(1):4-9.

Crary, S; Mack, J; Al-Huniti, A; Chang, V; Drolet, B; Hammill, A; Iacobas, I; Kelly, M; Winger, BA; Robledo, M; Blakesley, R; Patriquin, C; Mar, B; Sisk, B. ReInspire: A phase 2 study of mutant-selective PI3Kα inhibitor, RLY-2608, in adults and children with PIK3CA-related overgrowth spectrum and malformations driven by PIK3CA mutation. Blood. 2025; 146(Supplement 1):3092.

Davies, SM; Grimley, MS; Shrestha, A; Shova, A; Asnani, M; Kent, M; Sayani, F; Quinn, CT; Niss, O; Lutzko, CM; Witting, S; Latham, T; Bushman, FD; Malik, P. Gene Therapy with Reduced-Intensity Conditioning for Sickle Cell Disease. Transplantation and Cellular Therapy. 2025; 31(2):s2-s3.

Dei-Adomakoh, YA; Segbefia, CI; Latham, TS; Lane, AC; Dzefi-Tettey, K; Amissah-Arthur, K; Corquaye, O; Korang, L; Mensah, E; Ekpale, P; Seedah, D; Stuber, SE; Smart, LR; Ware, RE. Hydroxyurea for Children and Adults with Hemoglobin SC Disease. NEJM Evid. 2025; 4(2):EVIDoa2400402.

Dynan, L; Smith, RB; Quinn, CT. Inpatient and emergency healthcare utilization and payments for care of SCD: an analysis of all payers in Florida 2010-2019. Journal of Sickle Cell Disease. 2025; 2(1).

El Kassar, N; Dezern, AE; Abkowitz, J; Artz, A; Beerman, I; Bolton, K; Brooks, MM; Borate, U; Ershler, WB; Ganz, T; White, KE; Zhang, D; Ferrucci, L; Kuchel, GA. A proposed path to explaining the unexplained anemia of aging. The journals of gerontology. Series A, Biological sciences and medical sciences. 2026; 81(1).

Elgammal, Y; Zhang, W; Kalfa, TA. Molecular surprises in evaluations of red cell disorders. Hematology. American Society of Hematology. Education Program. 2025; 2025(1):370-376.

Elgammal, Y; Ntoumaziou, A; Romano, L; Blanc, L; Seu, K; Salomonis, N; Kalfa, T. Characterization of the human erythromyeloblastic islands (EMBIs) Blood. 2025; 146(Supplement 1):182-182.

Elgammal, Y; Hamdan, L; Risinger, M; Kostantinidis, D; Seu, K; Mcelhinney, K; Niss, O; Nemeth, E; Quinn, C; Ware, R; Kalfa, T. Biomarkers of ineffective erythropoiesis in patients with sickle cell anemia, at baseline and while treated with hydroxyurea, in comparison to patients with other iron-loading red cell disorders. Blood. 2025; 146(Supplement 1):4686.

Eng, W; Iacobas, I; Perkins, J; Zampino, G; Leoni, C; Buonuomo, PS; Simonetti, A; Goel, H; Briones, M; Huang, M; Goldmacher, G; Liaw, D; Hammill, A. Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndrome. Orphanet Journal of Rare Diseases. 2025; 20(1):375.

Engel, ER; Luchtman-Jones, L. Comment on: "Comment on: Bivalirudin During Thrombolysis With Catheter-Directed tPA in a Heparin-Refractory Patient: A Case Report": The Promise of Dilute Thrombin Time and Drug-Calibrated Assays for Improved Bivalirudin Monitoring. Pediatric Blood and Cancer. 2025; 72(1):e31418.

Fargo, J; Alleyne, M; Amankwah, E; Acharya, S; Wilson, H; Male, C; Rajpurkar, M; Tarango, C; Sidonio, Jr., R; Schulman, S; Goldenberg, N. Clinically relevant bleeding and heavy menstrual bleeding among patients <21 years old with provoked VTE: Findings from the multinational kids-DOTT trial. Blood. 2025; 146(Supplement 1):316-316.

Girgis, MK; Lopachin, TR; Hallett, TC; Briones, MA; Desai, NJ; Mcelhinney, KE; Ware, RE; Yee, MEM. Prolonged, Unintentional Overdose of Hydroxyurea in a Child With Sickle Cell Anemia. Pediatric Blood and Cancer. 2025; e70076.

Goldenberg, NA; Schulman, S; Kittelson, JM; Abshire, TC; Casella, JF; Dale, R; Halperin, JL; Hanson, J; Kessler, CM; Manco-Johnson, MJ; Mcdevitt, L; Sidonio, RF; Spyropoulos, AC; Steg, PG; Bonaca, MP. Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years. Journal of Thrombosis and Haemostasis. 2025; 23(2):651-656.

Grimley, M; Davies, SM; Shrestha, A; Shova, A; Asnani, M; Kent, M; Sayani, F; Quinn, CT; Niss, O; Lutzko, C; Witting, S; Latham, T; Bushman, FD; Malik, P. Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1/2 trial. Nature Medicine. 2025; 31(7):2204-2212.

Gwarzo, I; Coleman, KD; Mckinley, K; Ellison, AM; Alpern, ER; Corboy, J; Hariharan, S; Topoz, I; Wurtz, M; Nielsen, B; King, AA; Baumann, A; Frankenberger, W; Brousseau, DC. Opioid Timeliness in the Emergency Department and Hospitalizations for Acute Sickle Cell Pain. JAMA pediatrics. 2025; 179(11):1194-1202.

Haacker, L; Littner, L; Martin, M; Brokamp, C; Beck, AF; Luchtman-Jones, L. Anemia in Young Children and the Association With Socioeconomic Deprivation Indices. Pediatric Blood and Cancer. 2025; 72(7):e31663.

Haacker, L; Littner, L; Martin, M; Brokamp, C; Beck, AF; Luchtman-Jones, L. Reply to: Comment on Anemia in Young Children and the Association With Socioeconomic Deprivation Indices. Pediatric Blood and Cancer. 2025; 72(7):e31743.

Hamarsha, Q; Choaib, A; Azzam, M; Kawtharany, H; Khawandi, J; Alkhader, A; Nazzal, J; Alkasrawi, H; Khanfar, O; Betensky, M; Wilson, H; Woods, G; Velez-Yanguas, M; Mustafa, R. Title: Role of primary VTE prophylaxis in pediatric leukemia, lymphoma, and solid tumors: A systematic review and meta-analysis. Blood. 2025; 146(Supplement 1):3139-3139.

Hamdan, L; Elgammal, Y; Husami, A; Meznarich, J; Fasipe, F; Chonat, S; Mclemore, M; Schwartz, J; Sahib, S; Mccavit, T; Zhang, W; Lorsbach, R; Niss, O; Kalfa, T. Congenital dyserythropoietic anemia type I: Updated report from the congenital dyserythropoietic anemia registry of North America. Blood. 2025; 146(Supplement 1):4685-4685.

Hamdan, L; Elgammal, Y; Shova, A; Aygun, B; Quinn, C; Niss, O; Kalfa, T. Biomarkers of ineffective erythropoiesis in patients with transfusion- dependent thalassemia. Blood. 2025; 146(Supplement 1):4684-4684.

Hassanzadeh, S; Zeches, BA; Husami, A; Kalfa, TA; Knupp, CL; Richardson, MD. 467 Hereditary predisposition syndrome for myelodysplastic syndrome with SF3B1 mutation; a case report. American Journal of Clinical Pathology. 2025; 164(Supplement_1):aqaf121.272.

Hau, DK; Ruselu, G; Peck, RN; Downs, JA; Manyangu, GJ; Masoza, TS; Kisigo, GA; Smart, LR. Reducing Harm in Cultural Transition: Repurposing the 5 Stages of Grief Model for Global Health Experiences. Journal of Graduate Medical Education. 2025; 17(6):689-693.

Hau, DK; Fadhil, S; Lee, MH; Desderius, B; Willkens, M; Kalluvya, SE; Tebuka, E; Smart, LR; Peck, RN. Causes and Consequences of Persistent Anemia after 6 Months of Antiretroviral Therapy in Tanzania: An Observational Comparative Cohort Study. American Journal of Tropical Medicine and Hygiene. 2025; 112(1):234-241.

Hildenbrand, AK; Mara, CA; Murphy, B; Hood, AM; Johnson, Y; Shook, LM; Real, FJ; Nwankwo, C; Hackworth, R; Badawy, SM; Saving, KL; Treadwell, M; Quinn, CT; Crosby, LE. Engaging Parents of Children With Sickle Cell Disease in Shared Decision-Making for Hydroxyurea: The ENGAGE-HU Study. Pediatric Blood and Cancer. 2025; 72(5):e31639.

Iyer, VN; Vethanayagam, D; Al-Samkari, H; Beslow, LA; Chakinala, M; Decker, JE; Faughnan, ME; Galiatsatos, P; Gane, S; Geisthoff, U; White, AJ; Zhou, J; Friday, C; Clancy, M. Letter to the editor. European Archives of Oto-Rhino-Laryngology. 2025.

Jan, S; Steinway, C; Belton, T; Shults, J; Bennett, L; Teng, O; Griffis, H; Aygun, B; Appiah-Kubi, A; Apollonsky, N; Andemariam, B; Mulchan, SS; Rubin, D; Smith-Whitley, K. Community Health Worker and Mobile Health Interventions for Quality of Life Among Young Adults With Sickle Cell Disease: A Randomized Clinical Trial. JAMA Network Open. 2025; 8(11):e2543571.

Kalfa, TA. The diagnosis and treatment of red cell membrane disorders: algorithm for the general hematologist. Clinical Advances in Hematology and Oncology. 2025; 23(9):534-538.

Kawtharany, H; Azzam, M; Alkhader, A; Betensky, M; Hamarsha, Q; Abou Zeid, HK; Mansour, R; Tabak, C; Patel, P; Baghdadi, SL; Woods, G; Zia, A; Monagle, P; Mustafa, RA. Efficacy and safety of thrombolysis for pediatric venous thromboembolism: a systematic review and meta-analysis. Blood advances. 2025; 9(21):5512-5527.

Lang, AC; Mosley, C; Rosen, BL; Oke, E; Thompson, AA; Barriteau, C; Schwartz, L; Smith-Whitley, K; Crosby, LE; Shook, LM. Co-designing educational materials about SARS-CoV-2 (COVID-19) vaccines with individuals with sickle cell disease (SCD) and their families. Journal of Sickle Cell Disease. 2025; 2(1).

Latham, TS; Babich, SM; Yego-Kosgei, F; Czabanowska, K; Ware, RE. Building capacity for sickle cell stroke prevention in low-resource settings. Discover Public Health. 2025; 22(1):881.

Latham, T; Kiyaga, C; Hernandez, A; Nakafeero, M; Kadde, N; Khainza, P; Stuber, S; Ndeezi, G; Aceng, J; Ware, R. Health status of Ugandan children born with sickle cell anemia and congenital HIV identified through newborn screening. Blood. 2025; 146(Supplement 1):2668.

Latham, TS; Ware, RE; Shook, LM. Assessing educational needs of sickle cell anemia healthcare providers in sub-Saharan Africa and the Caribbean. Frontiers in Public Health. 2025; 13:1693285.

Latham, TS; Czabanowska, K; Babich, S; Yego-Kosgei, F; Shook, LM; Ware, RE. Primary Stroke Screening and Hydroxyurea Treatment for Sickle Cell Anemia in Pediatric Healthcare Settings in East and Central Africa: A Narrative Review of Capacity Gaps and Opportunities. Public Health Reviews. 2025; 46:1608359.

Lenahan, SF; Blackmore, A; Fenchel, M; Thomas, E; Palumbo, JS; Tarango, C. Recurrent thrombosis and major bleeding in children treated for VTE. Blood advances. 2025; 9(15):3824-3831.

Littner, L; Hu, J; Manuel, M; Gerber, C; Tarango, C. Inhibitors and Obesity: The Prevalence and Strength of Association in People With Haemophilia. Haemophilia. 2025; 31(6):1226-1235.

Littner, L; Thomas, E; Mooney, L; Doyle, J; Hendrickson, J; Tarango, C. Improving Time to Bleeding Disorder Treatment in the Emergency Department. Pediatric Blood and Cancer. 2025; 72(4):e31570.

Machogu, E; Aanyu-Tukamuhebwa, H; Mellencamp, K; Birungi, I; Namutangula, B; Namazzi, R; Latham, T; Opoka, R; Ware, R; Davis, SD; John, C. Benefits of Hydroxyurea in Mitigating Early Onset Lung Disease in Children With Sickle Cell Anemia. American Journal of Respiratory and Critical Care Medicine. 2025; 211(Abstracts):a1272-a1272.

Malec, L; Mathias, M; Dunn, AL; Nolan, B; Wong, N; Bystrická, L; Khan, U; Neill, G; Santagostino, E; Gunawardena, S; Tarango, C; Peyvandi, F. Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe hemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial. Journal of Thrombosis and Haemostasis. 2025; 23(11):3481-3491.

Malec, LM; Simpson, M; Khan, U; Neil, G; Mamikonian, L; Tarango, C. HTRS2025.P1.6 Clinical Outcomes Over 2 Years of Once-Weekly Efanesoctocog Alfa Treatment in Children From North America With Severe Hemophilia A in the Phase 3 XTEND-ed Long-Term Extension Study. Research and Practice in Thrombosis and Haemostasis. 2025; 9:103026.

Merkle, S; Lecras, T; Ricci, K; Hammill, A; Engel, E. Use of angiopoietin-2 as a biomarker in vascular anomalies beyond complex lymphatic anomalies. Blood. 2025; 146(Supplement 1):4877.

Monagle, P; Azzam, M; Bercovitz, R; Betensky, M; Bhat, R; Biss, T; Branchford, B; Brandão, LR; Chan, AKC; Faustino, EVS; Wilson, HP; Woods, G; Zia, A; Mustafa, RA. American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients. Blood advances. 2025; 9(10):2587-2636.

Mooney, JT; Sinha, C; Bakshi, N; Nuñez, A; Adkins, T; Thomas, S; Beasley, K; Akintobi, T; Crosby, L; Kashikar-Zuck, S; Dampier, C; Myer, GD; Kesar, T; Quinn, CT; Sil, S. Physical activity among adolescents and young adults living with chronic pain and sickle cell disease: a qualitative examination. Journal of Pediatric Psychology. 2025; 50(12):1079-1087.

Mooney, J; Adkins, T; Heatly, J; Howard, V; Dampier, C; Nuñez, A; Williams, J; Smith, E; Crosby, L; Kashikar-Zuck, S; Quinn, C; Kesar, T; Myer, G; Sil, S. Randomized controlled trial-in-progress of an interdisciplinary treatment program for youth with chronic SCD pain: Integrative strong body and mind training for sickle cell disease (I-STRONG) Blood. 2025; 146(Supplement 1):4753.

Muteti, M; Akoko, E; Nyakundi, C; Mochamah, G; Makale, J; Ombati, P; Tawa, B; Nyanjom, S; Boateng, LA; Ware, RE; Williams, TN; Uyoga, S. Erythrocyte alloimmunization in children with sickle cell anemia living in Kilifi, Kenya. Blood Global Hematology. 2025; 1(2):100016.

Namazzi, R; Mellencamp, KA; Opoka, RO; Datta, D; Lima-Cooper, G; Liepmann, C; Sherman, J; Rodriguez, A; Kazinga, C; Ware, RE; Abreu, M; Schwantes-An, T-H; John, CC; Conroy, AL. Circulating Immune Complexes and Glucose-6-Phosphate Dehydrogenase Deficiency Predict Recurrent Blackwater Fever in Ugandan Children With Severe Malaria. Journal of Infectious Diseases. 2025; 232(2):285-297.

Nieves, RM; Latham, T; Marte, N; Berges, M; Sánchez, LM; Urcuyo, G; Florencio, C; Gonzalez, C; Del Villar, P; Chen, S; Schultz, WH; Lane, AC; Mena, R; Ware, RE. Stroke prevention in Hispanic children with sickle cell anemia: the SACRED trial. Blood advances. 2025; 9(8):1791-1800.

Niss, O; Morin, CE; Hashemi, S; Alsaied, T; Lang, SM; Taylor, MD; Tasset, M; Malik, P; Quinn, CT. Longitudinal changes and predictors of cardiac extracellular volume fraction in sickle cell anemia. Blood Red Cells Iron. 2025; 1(3).

Niss, O; Ware, RE; Quinn, CT. A New First-Line Option for Pediatric ITP-Incremental Progress or Paradigm Shift? Journal of the American Medical Association (JAMA). 2025; 334(20):1802-1803.

Niss, O; Fenchel, M; Abrams, C; Quinn, C; Kutlar, A. Reassessing voxelotor safety and efficacy: Real-world outcomes from the ASH research collaborative data hub. Blood. 2025; 146(Supplement 1):6226-6226.

Niss, O; Morin, C; Hashemi, S; Alsaied, T; Lang, S; Tasset, M; Taylor, M; Malik, P; Quinn, C. Impact of disease genotype and severity of anemia on myocardial extracellular volume fraction in sickle cell disease (SCD) and non-SCD hemolytic anemias. Blood. 2025; 146(Supplement 1):2957.

Nnodu, O; Awuonda, B; Chirande, L; Kiyaga, C; Segbefia, C; Chunda-Liyoka, C; Franklin, P; Zapfel, A; Benoit, M; Thompson, A; Coetzer, T; Ware, R; Novelli, E; Green, NS. The ASH consa consortium on newborn screening in Africa for sickle cell disease: Interim updates of progress in screening, follow-up and supporting initiatives. Blood. 2025; 146(Supplement 1):944-944.

Ntoumaziou, A; Husami, A; Risinger, M; Elgammal, Y; Voulgaridou, A; Leister, J; Seu, K; Zhang, W; Kalfa, T. Hereditary spherocytic pyropoikilocytosis: Expanding the clinical and genetic spectrum of red blood cell membrane disorders. Blood. 2025; 146(Supplement 1):4667.

Padarti, A; Quinn, CT; Kwiatkowski, JL; Mcnaull, M; Kirkham, FJ; Plumb, P; Hynan, LS; Dowling, MM. Prevalence of Antiplatelet and Anticoagulation Therapy in Children with Sickle Cell Anemia and Stroke. Pediatr Stroke. 2025; 11:111-140.

Pappano, E; Eskandari, N; Ruiz, MA; Ren, G; Zhang, X; Han, J; Ivy, Z; Njoku, F; Farooqui, M; Molokie, R; Gordeuk, V; Gladwin, M; Malik, P; Quinn, C; Saraf, S. Renin-angiotensin-aldosterone system inhibitors exacerbate anemia in sickle cell disease. Blood. 2025; 146(Supplement 1):297-297.

Power-Hays, A; Quinn, CT. Liquid Hydroxyurea (Xromi) for Children With Sickle Cell Anemia: A New Solution Compounding Existing Problems. Pediatric Blood and Cancer. 2026; e70143.

Power-Hays, A; Namazzi, R; Dong, M; Kazinga, C; Kato, C; Aliwuya, S; Mcelhinney, K; Conroy, AL; Lane, A; John, C; Vinks, AA; Latham, T; Opoka, RO; Ware, RE. The feasibility of pharmacokinetic-based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trial. British Journal of Clinical Pharmacology. 2025; 91(6):1865-1872.

Power-Hays, A; Namazzi, R; Dong, M; Kazinga, C; Kato, C; Aliwuya, S; Mcelhinney, K; Conroy, AL; Lane, A; John, C; Vinks, AA; Latham, T; Opoka, RO; Ware, RE. The feasibility of pharmacokinetic-based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trial. British Journal of Clinical Pharmacology. 2025; 91(6):1865-1872.

Power-Hays, A; Mcelhinney, KE; Williams, TN; Mochamah, G; Olupot-Olupot, P; Paasi, G; Reid, ME; Rankine-Mullings, AE; Opoka, RO; John, CC; Stuber, SE; Latham, TS; Vinks, AA; Ware, RE. Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations. Blood advances. 2026; 10(2):418-427.

Power-Hays, A; Namazzi, R; Mcelhinney, K; Kincaid, A; Kato, C; Aliwuya, S; Opoka, R; Conroy, A; John, C; Hume, HA; Stuber, S; Latham, T; Ware, R. Full assessment of clinical transfusion support (FACTS): A prospective Study to determine the burden of sickle cell anemia on pediatric blood transfusion use in a malaria-endemic region in Africa. Blood. 2025; 146(Supplement 1):300-300.

Power-Hays, A; Kincaid, A; Mcelhinney, K; Latham, T; Quinn, C; Frenck, R; Ware, R. Measles vaccine-induced sero-protection among children with sickle cell anemia. Blood. 2025; 146(Supplement 1):1168.

Power-Hays, A; Namazzi, R; Kato, C; Mcelhinney, KE; Conroy, AL; Hume, H; John, C; O'hara, SM; Stuber, SE; Lane, A; Latham, TS; Opoka, RO; Ware, RE. Pharmacokinetic-Guided Hydroxyurea to Reduce Transfusions in Ugandan Children with Sickle Cell Anemia: Study Design of the Alternative Dosing And Prevention of Transfusions Trial. Acta Haematologica. 2025; 148(2):208-219.

Quinn, C; Kincaid, A; Mcelhinney, K; Korpik, J; Kalfa, T; Ware, R. Feasibility, reliability, and accuracy of point-of-care measurements of fetal hemoglobin. Blood. 2025; 146(Supplement 1):4739-4739.

Quinn, CT; Ware, RE. The modern use of hydroxyurea for children with sickle cell anemia. Haematologica. 2025; 110(5):1061-1073.

Quinn, CT; Ware, RE. The Voxelotor Effect: Decreased Affinity for New Drugs for Sickle Cell Disease? Pediatric Blood and Cancer. 2025; 72(3):e31475.

Richmond, A; Hansen, S; Dykman, M; Adams, DM; Antaya, RJ; Bennett, JT; Frieden, IJ; Hammill, AM; Liang, MG; Maheshwari, M; Chamlin, S; Cotton, C; Lalor, L; Lee, LW. 44: Capillary Malformation-Arteriovenous Malformation Syndrome: Proposed Consensus Guidelines. Journal of Investigative Dermatology. 2025; 145(3):e12.

Rineer, S; Kwakye, D; Ambrose, EE; Jason, IDP; Smart, LR. Validation of Pediatric Self-Report Pain Scales in Sub-Saharan Africa: A Systematic Review. Journal of Pain and Symptom Management. 2025; 69(2):e103-e112.

Rios, CR; Lu, M; Hanson, K; Savidge, E; Ward, T; Korpik, J; Reynaud, M; Ware, R; Kalfa, T; Quinn, C. Imaging flow cytometry for detection of red blood cell inclusions: A quantitative approach to assess splenic filtration function in sickle cell disease. Blood. 2025; 146(Supplement 1):1188.

Risinger, M; Zhang, W; Kalfa, TA. Advances on the genetic basis of red cell membrane disorders. Current Opinion in Hematology. 2025; 32(5):279-286.

Seither, K; Cortezzo, DE; Mckinney, D; Ricci, K; Riddle, S. Congenital Lymphatic Malformations. NeoReviews. 2025; 26(8):e578-e586.

Setayesh, T; Tijani, A; Kaur, H; Khanal, S; Zhu, Z; Chi, M; Kincaid, A; Ware, R; Malik, P. Oxidative stress and hemoglobin-c denaturation drive hemoglobin SC pathophysiology and can be ameliorated by antioxidants and hydroxyurea. Blood. 2025; 146(Supplement 1):7.

Shook, LM; House, B; Farrell, CB; Stewart, R; Lanzkron, S; King, AA; Varughese, T; Strouse, JJ; Treadwell, M; Kanter, J. Challenges of Engaging Primary Care Providers in Specialized Telementoring Education About Sickle Cell Disease for Sickle Cell Specialists: Results from the Sickle Cell Disease Training and Mentoring Program for Primary Care Providers (STAMP) Project ECHO. AJPM Focus. 2025; 4(1):100304.

Shook, LM; Haygood, D; Quinn, CT. Clinical Utility of the Addition of Molecular Genetic Testing to Newborn Screening for Hemoglobinopathies for Confirmation of Alpha-Thalassemia Trait. International Journal of Neonatal Screening. 2025; 11(1).

Shukla, RP; Aroosh, M; Cazelles, R; Ware, RE; Vinks, AA; Ben-Yoav, H. Microsensor Array for the Electrochemical Analysis of Hydroxyurea in Blood Samples of Children Affected by Sickle Cell Anemia. Analytical Chemistry. 2025; 97(44):24399-24414.

Sirotich, E; Chowdhury, SR; Modi, D; Guyatt, G; St John, M; Eisa, K; Cuker, A; Beck, CE; Grace, RF; Yan, JW; Kim, D; Thabane, L; Zeraatkar, D; Arnold, DM. Critical bleeding in adults and children with immune thrombocytopenia: a multicenter cohort study. Blood advances. 2025; 9(13):3238-3248.

Sisk, BA; Eng, W; Aye, J; Mack, J; Tran, A; Ogino, J; Pearson, E; Bies, J; Smink, G; Shah, SD; Echols, T; Kumar, S; Fox, M; King, KA. Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States. Pediatric Blood and Cancer. 2025; 72(6):e31661.

Smart, L; Dei-Adomakoh, Y; Lane, A; Ekpale, P; Koni, L; Corquaye, O; Mensah, E; Stuber, S; Latham, T; Segbefia, C; Ware, R. Benefits of hydroxyurea in hemoglobin SC: Results of the open-label phase of the prospective identification of variables as outcomes for treatment (PIVOT) trial. Blood. 2025; 146(Supplement 1):409.

Smart, L; Ambrose, E; Charles, M; Mcelhinney, K; Lane, A; Stuber, S; Latham, T; Ware, R. Pharmacokinetic (PK)-guided vs weight-based dosing of hydroxyurea for tanzanian children with sickle cell anemia. Blood. 2025; 146(Supplement 1):2959-2959.

Thornburg, CD; Van Den Berg, HM; Chandler, M; Malec, L; Manuel, M; O'neill, C; Recht, M; Taggart, E; Carpenter, SL. Inhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US cohort study. Blood Vessels, Thrombosis & Hemostasis. 2025; 2(3):100082.

Todd, K; Hogue, SJ; Tweddell, JS; Reagor, JA; Mullins, E; Block, MG; Rosenfeldt, L; Francisco, B; Jodele, S; Sharma, BK; Lane, A; Slusher, C; Kharnaf, M; Morales, DLS; Palumbo, JS. Hemostatic derangements associated with cardiopulmonary bypass predict outcomes in pediatric patients undergoing corrective heart surgery. Journal of Thrombosis and Haemostasis. 2025; 23(2):492-503.

Tomlinson, GA; Backeljauw, P; Mochamah, G; Smart, LR; Latham, TS; Ware, RE; Williams, TN. Development of disease-specific growth curves from Kenyan children with sickle cell anemia. Blood Global Hematology. 2025; 1(3):100031.

Tozzo, V; Craig, J; Omololu, SO; Genco, M; Smith, EP; Thibault, D; Arbabi, S; Abplanalp, W; Quinn, CT; Lindsell, CJ; Bergenstal, RM; Franco, RS; Higgins, J; Cohen, RM. 1013-P: Estimates of Mean Red Blood Cell Age (MRBC) Obtained with Continuous Glucose Monitoring (CGM)-Based Computational Methods Are Comparable to Those Obtained with Stable Isotope (SI) In Vivo Measurements. Diabetes. 2025; 74(Supplement_1).

Tshilolo, L; Tomlinson, G; Smart, L; Latham, T; Olupot-Olupot, P; Santos, B; Aygun, B; Stuber, S; Lane, A; Williams, T; Ware, R. Splenomegaly patterns and clinical impact in African children with sickle cell anemia on hydroxyurea treatment. Blood. 2025; 146(Supplement 1):2971-2971.

Vore, E; Cooke-Barber, J; Brungardt, J; Tiao, G; Hammill, A; Ricci, K; Patel, M; Dasgupta, R. Management, Trends, and Recommendations for Intra-abdominal Lymphatic Malformations: A Single-Center Retrospective Review. Journal of Pediatric Surgery. 2025; 60(4):162223.

Ware, R; Opoka, R; Latham, T; Kasirye, P; Kasembo, P; Hume, HA; Birungi, I; Kadde, N; Wambaka, B; Nakafeero, M; Lane, A; John, C. Safety and efficacy of ten years of hydroxyurea treatment for young children with sickle cell anemia in Uganda. Blood. 2025; 146(Supplement 1):412.

Warner, MA; Hanson, AC; Johnson, ML; Go, RS; Gajic, O; Schulte, PJ; Kor, DJ; Serra, M; Kalfa, TA; Blanc, L. Longitudinal changes in haemoglobin, iron stores, and inflammatory markers following surgery and in critical illness: an analysis from the Practical Anaemia Bundle for Sustained Blood Recovery randomised clinical trial. British Journal of Anaesthesia. 2025.

Williams, TN; Ware, RE. Malaria prophylaxis in sickle cell anaemia: some answers, more questions. The Lancet Infectious Diseases. 2025; 25(6):601-602.

Wilson, HP; Mosha, M; Miller, A; Betensky, M; Amankwah, E; Fargo, J; Thornburg, CD; Tarango, C; Acharya, S; Male, C; Narang, S; Schulman, S; Goldenberg, NA. Secondary Anticoagulation Use in Patients < 21 Years Old following Primary Anticoagulant Treatment for Provoked Venous Thromboembolism: Findings from the Kids-DOTT Trial. Seminars in Thrombosis and Hemostasis. 2025; 51(3):343-347.

Zhang, W; Elgammal, Y; Husami, A; Voulgaridou, A; Sakthivel, H; Cannon, M; Bonavita, L; Grimley, M; Heeney, M; Ntoumaziou, A; Risinger, M; Yang, E; Kalfa, T. Transcriptomic analysis uncovers hidden intronic and synonymous pathogenic variants in red cell membrane disorders. Blood. 2025; 146(Supplement 1):282-282.

Zia, A; Nelson, MD; Ren, J; Zhang, S; Mattrey, RF; Han, BL; Hussain, T; Greer, JS; Al-Qahtani, M; Malone, K; Male, C; Levine, B; Balmain, BN; Babb, TG. The Functional Characterization of Venous Thromboembolic Disease (FUVID) study: rationale, design, and methods of a prospective, observational, multicenter study to evaluate mechanisms of exercise intolerance and dyspnea following pediatric pulmonary embolism. Research and Practice in Thrombosis and Haemostasis. 2025; 9(1):102669.